Continuous positive airway pressure (CPAP) is the treatment of choice for obstructive sleep apnea (OSA), and studies have shown that there is a correlation between patient adherence and treatment outcomes. Newer CPAP machines can track adherence, hours of use, mask leak, and residual apnea–hypopnea index (AHI). Such data provide a strong platform to examine OSA outcomes in a chronic disease management model in which CPAP adherence is tracked over time. To assess CPAP adherence and efficacy, tracking systems have been implemented. Such systems monitor CPAP efficacy (residual sleep-disordered breathing), hours of CPAP use, mask leak, and a number of different flow signals. However, there are no standards for capturing CPAP adherence data, scoring flow signals, or measuring mask leak, or for how clinicians should use these data.

Methods: American Thoracic Society (ATS) committee members were invited, based on their expertise in OSA and CPAP monitoring. Their conclusions were based on both empirical evidence identified by a comprehensive literature review and clinical experience.

Results: CPAP usage can be reliably determined from CPAP tracking systems, but the residual events (apnea/hypopnea) and leak data are not as easy to interpret as CPAP usage and the definitions of these parameters differ among CPAP manufacturers. Nonetheless, ends of the spectrum (very high or low values for residual events or mask leak) appear to be clinically meaningful.

Conclusions: Providers need to understand how to interpret CPAP adherence tracking data. CPAP tracking systems are able to reliably track CPAP adherence. Nomenclature on the CPAP adherence tracking reports needs to be standardized between manufacturers and AHIflow should be used to describe residual events. Studies should be performed examining the usefulness of the CPAP tracking systems and how these systems affect OSA outcomes.

Keywords: CPAP adherence; sleep apnea; CPAP tracking systems

EXECUTIVE SUMMARY

Obstructive sleep apnea (OSA) is an extremely common condition and is associated with significant morbidity and mortality (1–18). Optimal treatment of sleep apnea is critical because sleep-disordered breathing is associated with the increased risk of vehicular crashes and cardiovascular morbidity and mortality (6, 9–18). Continuous positive airway pressure (CPAP) is the treatment of choice for sleep apnea (19–22). Increased CPAP adherence has been shown to improve outcomes such as daytime sleepiness, quality of life, and mortality (23–25). OSA should be considered in chronic disease management in which CPAP adherence is tracked over time. To assess CPAP adherence and efficacy, tracking systems have been implemented. Such systems monitor CPAP efficacy (residual sleep-disordered breathing), hours of CPAP use, mask leak, and a number of different flow signals. However, there are no standards on how to use the data from these new CPAP tracking systems nor do we have evidence that these systems ultimately improve outcomes. See the online supplement for full discussion of the literature on the accuracy of the residual AHI and mask leak.

The purpose of this document is to (1) review the data (adherence, leak, efficacy, flow signals) obtained from CPAP adherence tracking systems and the reliability of these data; (2) examine the use of CPAP tracking systems in clinical practice; (3) discuss outcomes that satisfy payer reimbursement criteria for chronic CPAP use; and (4) propose research questions to address important issues in relation to CPAP tracking and OSA outcomes.

Major conclusions of this clinical statement:

- CPAP adherence tracking systems intuitively seem useful; however, there are few studies that provide data that show that these systems improve CPAP usage or OSA outcomes.
- Notwithstanding, CPAP adherence tracking systems provide a strong platform to generate outcome data in a chronic disease management model, which is how the treatment of OSA should be considered.
- CPAP usage can be reliably determined from CPAP tracking systems (although there can be technical failures with card transmission of data) and such data should be routinely examined in patients with OSA. CPAP adherence needs to be monitored sequentially over time.
• To optimally interpret residual events on the CPAP adherence tracking reports, providers need to understand the different definitions for apneas and hypopneas from each manufacturer of CPAP tracking systems.

• The residual apneas and hypopneas and mask leak data from CPAP tracking systems are not easy to interpret and the definitions of these parameters differ among each of the CPAP adherence tracking system manufacturers.

• The value of CPAP adherence monitoring for clinical decision making based solely on intermediate values for the residual apnea–hypopnea index (AHI), residual apnea index, or mask leak is unclear and, therefore, additional research is indicated.

• Very high or low values for residual apneas/hypopneas or mask leak appear to be clinically useful in chronically managing patients with sleep apnea.

• Current clinical care systems are not optimally configured for examining data from CPAP adherence tracking systems.

• Documentation of CPAP adherence should be accepted between 7 and 90 days, rather than the current 31- to 90-day requirement, and CPAP adherence should be monitored long term (for as long as the patient is using CPAP).

• Nomenclature on the CPAP adherence tracking reports needs to be standardized between manufacturers and the AHIFlow should be used to describe residual events.

• Studies should be performed to examine the usefulness of the CPAP tracking systems and how these systems affect OSA outcomes.

INTRODUCTION

Obstructive sleep apnea (OSA) is an extremely common condition and is associated with considerable morbidity and mortality. The Wisconsin Sleep Cohort Study found that 4% of middle-aged males and 2% of middle-aged females had OSA (1). The prevalence of OSA is much higher (on the order of 80%) in certain populations (overweight type 2 diabetics, bariatric surgery patients) (2–5). Consequences of OSA can be broadly divided into those related to neurocognitive function (e.g., excessive sleepiness) and those related to the cardiovascular and metabolic systems. Excessive daytime sleepiness produces a number of different problems for patients with OSA, the most serious of which is motor vehicular accidents (MVAs). Studies in driving simulators indicate that OSA impairs driving ability (6), and crashes are increased among individuals who have OSA compared with matched individuals who do not have OSA (7). Patients with OSA can be as impaired in driving skills as those who are over the legal blood alcohol concentration limit (6). The Sleep Heart Health and other studies have demonstrated that patients with OSA are at increased risk for hypertension (9–11), myocardial infarction (MI) (12, 13), stroke (14), and death (15–18). Nocturnal cardiac arrhythmias including atrial fibrillation, sinus bradycardia/tachycardia, supra/ventricular tachycardias, heart block, and sinus pauses have all been reported during apneic episodes (26–29). Mild-to-moderate pulmonary hypertension can develop in patients with OSA (30–32) although overt right heart failure is uncommon in the absence of other contributing factors. Studies have shown that patients with moderate-to-severe OSA have increased mortality (10 to 20 yr after the diagnosis has been made) (16–18). On the basis of the public health impact of the increased risk of vehicular crashes and the cardiovascular morbidity and mortality, optimal treatment of OSA is clearly important.

Continuous positive airway pressure (CPAP) is the treatment of choice for OSA (19–22). CPAP has been shown to improve sleep architecture, decrease risk of MVAs (33–35), improve quality of life (23, 36), and decrease neurocognitive and cardiovascular consequences associated with OSA (12, 22, 37–47). Several consensus statements have examined the efficacy of CPAP in the treatment of OSA (22, 47, 48). Moreover, CPAP adherence (measured as hours of use per night) has been shown to modify outcomes (23–25). The importance of adherence to treatment has been shown by studies showing the return of sleepiness and impairments in simulated driving ability in as little as one night off CPAP (49, 50). Moreover, CPAP withdrawal resulted in a rapid recurrence of apneic events, daytime sleepiness, increased blood pressure, and increased heart rate (51).

To assess CPAP adherence and efficacy, tracking systems have been implemented by CPAP manufacturers. Such systems monitor CPAP efficacy (residual sleep-disordered breathing), hours of CPAP use, mask leak, and a number of different flow signals. However, there are no guidelines on how to use the data from these new CPAP tracking systems nor do we have evidence that these systems ultimately improve outcomes. Furthermore, methods of measuring and reporting the parameters from CPAP adherence downloads are inconsistent between manufacturers and not well validated. CPAP adherence tracking systems are available to most providers who care for patients with OSA. Yet there are few studies examining the usefulness of CPAP tracking systems even though they are commonly used in clinical practice to manage patients with OSA (52). Technological advances rather than evidence-based medicine are driving the increased use of CPAP tracking systems in this rapidly changing environment. CPAP adherence tracking systems have not been tested to show improved outcomes but their use is intuitively logical, such that CPAP adherence tracking is now a requirement for Medicare and other payers to continue reimbursement for CPAP beyond the first 3 months of treatment.

CPAP adherence tracking systems provide a strong platform to generate outcome data in a chronic disease management model, which is how the treatment of OSA should be considered. We have the ability to link patterns of use to salient disease outcomes and responses to treatment. It is much easier to determine CPAP adherence outcomes for OSA treatment than it is to determine treatment outcomes for most chronic disorders including asthma, hypertension, arthritis, or chronic obstructive pulmonary disease. As such, the OSA field has the opportunity to take a leading role in understanding interventions to improve adherence to therapy. Such strategies may be critical to improving clinical outcomes. We can track CPAP use in timeframes ranging from hours of use during one night, to use over months to even years. This ability permits the linking of patterns of use to cardiovascular outcomes and can help direct clinical decision making.

The goals of this statement are as follows:

• To review CPAP adherence tracking systems, including the data that they track (adherence, leak, efficacy, flow signals) and the reliability of these data.

• To examine the use of CPAP tracking systems in clinical practice.

• To discuss clinical outcomes (CPAP usage and others) that could be measured to satisfy payer reimbursement criteria for chronic CPAP use.

• To address important research questions in relation to CPAP tracking and OSA outcomes.
These tracking systems can be used in patients receiving continuous positive airway pressure (CPAP) therapy. However, objective CPAP adherence data may be more difficult to obtain than CPAP adherence downloads. Refill rates of CPAP accessories have also been used as a surrogate measure of adherence, but these tracking systems can be used in patients receiving conventional CPAP, auto-CPAP, bilevel, auto-bilevel, or adaptive servo-ventilation. The specific pressure data reported in each of these systems differ, but regardless of the type of positive airway pressure unit the reports provide information on adherence, residual AHI, and mask leak. Table 1 reviews the adherence data that can be tracked from CPAP units. Table 2 (52, 59–62) examines the specific event detection methodology for each CPAP manufacturer. Table 3 (63) defines how leaks and large leaks are measured, and Figure 1 provides a clinical algorithm for the use of CPAP adherence data. The specific details regarding performance evaluation of CPAP device–derived data are described extensively in the online supplement.

METHODS

Committee Process

The Statement was conceived by the planning committee of the Sleep and Respiratory Neurobiology Assembly of the ATS, and was chair (Richard J. Schwab) initiated. Committee members were invited on the basis of their scientific/clinical expertise in investigation/management of OSA and CPAP monitoring. Most of the committee members were from academic institutions within the United States, because the focus of this document was directed toward providers within the United States. Meetings were held at the American Thoracic Society annual international conference and consensus on all conclusions was reached among members of the committee by discussion. All members reviewed and approved the entire final draft by e-mail. All committee members were required to disclose potential conflicts of interest, which were vetted according to the policies of the ATS. See Methods Table in the online supplement.

Literature Search

Committee members compiled reference material germane to the assessment of CPAP monitoring, adherence, and outcomes in OSA. In addition, a literature review was conducted, based primarily on PubMed (from 2000 to November 2012), medical library catalog searches, and manual reviews of the bibliographic and abstract sections for the annual meetings of the American Thoracic Society, the Associated Professional Sleep Societies, other relevant professional societies, and reference lists of selected papers and chapters. Key words for the literature search included the following: CPAP adherence tracking systems, CPAP adherence, CPAP compliance, CPAP use, and CPAP tracking systems. This clinical statement focused on peer-reviewed articles, reviews, and editorials, in which primary data, conclusions, and/or positions were available. However, because there were sparse primary data on CPAP adherence tracking systems, conclusions were primarily based on uncontrolled observations and the clinical experience of our expert committee.

CPAP ADHERENCE TRACKING SYSTEMS

Why do we care about CPAP adherence and hours of use? Although CPAP improves both the neurobehavioral (daytime sleepiness [23, 24, 41, 42], MVA [33–35, 53]) and cardiovascular consequences of OSA (hypertension [9–11, 39, 40, 43, 44, 46–48], MI [12, 13], stroke [14], atrial fibrillation [26–29]), the important question is whether or not increased CPAP hours of use further improve these outcomes. Weaver and colleagues and Antic and colleagues have independently shown that increasing the number of hours of CPAP use results in better outcomes (23, 24). Specifically in these studies, increased hours of CPAP use improved measures of daytime sleepiness (e.g., the Epworth Sleepiness Scale [ESS], the Multiple Sleep Latency Test [MSLT], and scores in the Functional Outcomes of Sleep Questionnaire [FOSQ]). Likewise, cardiovascular and mortality outcomes correlated with the amount of CPAP use (12, 25, 54–56). Thus, it is important to track CPAP use so that patients with OSA who use their device for only a short duration may be intervened on.

Objectively measured CPAP adherence is more reliable than self-reported adherence, because self-reported CPAP use has been shown to correlate poorly with actual hours of use (57). Refill rates of CPAP accessories have also been used as a surrogate measure for long-term CPAP adherence (58) but such data may be more difficult to obtain than CPAP adherence downloads. These tracking systems can be used in patients receiving conventional CPAP, auto-CPAP, or bilevel, auto-bilevel, or adaptive servo-ventilation. The specific pressure data reported in each of these systems differ, but regardless of the type of positive airway pressure unit the reports provide information on adherence, residual AHI, and mask leak. Table 1 reviews the adherence data that can be tracked from CPAP units. Table 2 (52, 59–62) examines the specific event detection methodology for each CPAP manufacturer. Table 3 (63) defines how leaks and large leaks are measured, and Figure 1 provides a clinical algorithm for the use of CPAP adherence data. The specific details regarding performance evaluation of CPAP device–derived data are described extensively in the online supplement.

BARRIERS TO USING CPAP ADHERENCE TRACKING SYSTEMS IN CLINICAL PRACTICE

There are other barriers to incorporating CPAP adherence tracking systems routinely in clinical practice. The lack of standardization precludes interoperability with existing electronic medical records. Data profiles are not standardized between the different proprietary tracking systems and the reports are not yet easily exportable to electronic medical records (presently the reports need to be scanned into electronic medical records, which takes time). Customized software should be written to allow more transparent input of CPAP adherence data to a given electronic medical record. Connectivity to server databases can be suboptimal (particularly when using multiple homecare providers and device companies). Current care delivery systems are not configured for this type of data management and examining the CPAP tracking reports can slow down patient flow in a busy sleep practice. Faxed reports are cumbersome and provide a black-and-white background, which is problematic because many of the reports need to be displayed in color.

<table>
<thead>
<tr>
<th>TABLE 1. ADHERENCE DATA DERIVED FROM CONTINUOUS POSITIVE AIRWAY PRESSURE TRACKING SYSTEMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date ranges of device usage</td>
</tr>
<tr>
<td>Total number of nights the CPAP was used</td>
</tr>
<tr>
<td>Total number of nights the CPAP was not used</td>
</tr>
<tr>
<td>Percentage of nights with CPAP usage</td>
</tr>
<tr>
<td>Percentage of nights with CPAP usage &gt; 4 h/night</td>
</tr>
<tr>
<td>Percentage of nights with CPAP usage &lt; 4 h/night</td>
</tr>
<tr>
<td>Average usage on nights when CPAP was used</td>
</tr>
<tr>
<td>Average usage on all nights</td>
</tr>
</tbody>
</table>

Definition of abbreviation: CPAP = continuous positive airway pressure.
There are also possible medical/legal ramifications of CPAP tracking systems. For instance, if a school bus driver is using CPAP and has a motor vehicle accident, CPAP tracking data could be examined during a legal proceeding. The bus driver’s CPAP use the night before an accident could be examined as well as CPAP use during the week before the motor vehicle accident. The physician taking care of this bus driver could also face medical/legal risk. If the bus driver’s CPAP use was not ideal, if there was a high residual AHI or a large CPAP mask leak, it could be argued that the physician should have acted on these data. However, in such a scenario it is not clear how much CPAP use is enough or what level of residual AHI matters.

**METRICS TO DETERMINE CPAP EFFECTIVENESS**

Although there are important concerns with CPAP tracking systems, third-party payers are mandating the use of CPAP adherence tracking systems to objectively document therapeutic use to reimburse CPAP. The Centers for Medicare and Medicaid Services (CMS) have developed specific guidelines on CPAP (or bilevel) reimbursement. Initial CPAP reimbursement is limited to 12 weeks (67). Continued coverage of a CPAP device beyond the first 3 months of therapy requires that, no sooner than Day 31 but no later than Day 91 after initiating therapy, the treating physician must conduct a clinical reevaluation and document that the patient is benefiting from CPAP therapy. Clinical benefit is demonstrated by a face-to-face clinical reevaluation by the treating provider with documentation that symptoms of OSA are improved with objective evidence of CPAP adherence. Adherence is defined as use of CPAP for at least 4 hours/night on 70% of nights during a consecutive 30-day period any time during the first 3 months of initial usage. However, there is insufficient evidence to support this definition of CPAP adherence as a threshold for improved neurocognitive and cardiovascular outcomes. As described previously, there is a dose–response relationship between amount of nightly CPAP use and clinical outcomes (23–25). These data indicate that even subjects who use CPAP for only 2 hours show improvement in measures of some outcomes (ESS, FOSQ, MSLT). Moreover, several studies (some randomized controlled trials) have shown improvements in daytime sleepiness, functional outcomes, cognitive function, and blood pressure in patients treated with CPAP for less than 4 hours/night, 70% of the nights (23, 44).

**TABLE 2. EVENT DETECTION ALGORITHMS**

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Apnea Event Detection</th>
<th>Hypopnea Event Detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>ResMed unit (S9 model)</td>
<td>Apnea is defined when the 2-s moving average root mean square ventilation (based on a pneumotachograph) falls below 25% of the long-term ventilation for 10 s</td>
<td>Hypopnea is defined when all of the following conditions are met: 1. The 12-s moving average root mean square ventilation falls below 50% of the long-term ventilation 2. The hypopnea is not immediately followed by an apnea 3. The hypopnea contains one or more partially obstructed breaths</td>
</tr>
<tr>
<td>Phillips Respironics unit (System One model)</td>
<td>Apnea is detected after a moving window of 3-4 min is established and flow decreases by more than 80% for at least 10 s</td>
<td>Hypopnea is detected when moving window of 3-4 min is established and flow decreases by 40–80% for at least 10 s</td>
</tr>
<tr>
<td>DeVilbiss Healthcare IntelliPAP unit (SmartCode remote data retrieval system)</td>
<td>A reduction in a flow signal of &gt;90% of the baseline flow for 10 s &gt;80% reduction in flow relative to a baseline determined from previous breaths</td>
<td>A reduction in a flow signal of &gt;50% of the baseline flow for 10 s &gt;40% reduction in flow relative to a baseline determined from previous breaths</td>
</tr>
<tr>
<td>Fisher &amp; Paykel InfoSmart software</td>
<td>Apnea is defined when the 2-s moving average root mean square ventilation (based on a pneumotachograph) falls below 25% of the long-term ventilation for 10 s</td>
<td>Hypopnea is defined when all of the following conditions are met: 1. The 12-s moving average root mean square ventilation falls below 50% of the long-term ventilation 2. The hypopnea is not immediately followed by an apnea 3. The hypopnea contains one or more partially obstructed breaths</td>
</tr>
</tbody>
</table>
The CMS criteria assume that CPAP treatment has a threshold effect and therefore do not address whether outcomes may have a linear response with much lower levels of CPAP use (23). The CMS requirements also mandate an in-laboratory polysomnogram if CPAP was prescribed on the basis of portable monitoring and the patient subsequently fails the 90-day use criteria. The validity of this requirement is unclear, especially in the patient whose portable study demonstrates unequivocal severe OSA.

What specific clinical outcomes independent of the data from CPAP tracking systems should be measured to ascertain a salutary response to CPAP? Such outcomes could include (1) subjective daytime sleepiness (ESS) [it should be noted, however, that the ESS is highly variable when administered sequentially to a clinical OSA population (70)], etc.; (2) objective daytime sleepiness (PVT [Psychomotor Vigilance Test], MSLT, MWT [Maintenance of Wakefulness Test]); (3) self-reported improvement in the presenting symptom (i.e., nocturia, headache, sleep fragmentation, insomnia); (4) blood pressure; (5) cardiovascular outcomes (MI, hypertension, cardiovascular accident, heart failure, arrhythmias, improved insulin resistance or diabetic control); (6) cognitive functioning (memory, neurocognitive testing); (7) quality of life (FOSO, SF [Short Form Health Survey] 36, Calgary Sleep Apnea Specific Quality of Life Instrument [SAQLI] (71, 72), depression scales); (8) sexual function; (9) spousal outcomes; and (10) MVAs. It is likely that specific outcomes (e.g., cardiovascular vs. cognitive) in various populations (e.g., old vs. young, etc.) will be dependent on a range of CPAP durations.

We believe optimal clinical practices (largely based on clinical experience) for chronically managing CPAP in patients with OSA should include the following:

- We encourage patients to use CPAP whenever they are asleep (during the day or night).
- We consider patients adherent if they regularly use CPAP for more than 4 h/night or if they use CPAP for more than 2 h/night and are making progress toward improved daytime sleepiness as measured by the ESS, subjective improvement in quality of life, or improvement of other OSA-associated health impairments (e.g., diabetes, hypertension). This reflects our belief that partial use is better than no use, although our goal is always to achieve full-time CPAP use during sleep.
- We assess these outcomes soon after the initiation of CPAP therapy, because data demonstrate that CPAP adherence is typically established early in the course of treatment, perhaps as early as the first 3–7 days (73–80). We measure the outcomes after 1 week, 4–6 weeks, 12 weeks, 6 months, 1 year after the initiation of CPAP, and then monitor them yearly thereafter.

Regardless of the specific time frame these outcomes need to be measured longitudinally because OSA should be viewed and treated as a chronic disease. Addressing CPAP intolerance early may improve CPAP adherence, whereas waiting for the requisite minimum 30 days may allow entrenched problems to result in abandonment of, or suboptimal adherence to, CPAP. The current 31- to 90-day requirement for documentation of CPAP adherence is arbitrary and not supported by evidence. The committee members prefer to document CPAP adherence earlier (i.e., 7–90 d) because there is evidence that addressing CPAP intolerance early may improve long-term adherence (81–83). Moreover, CPAP adherence needs to be monitored long term (for as long as the patient is using CPAP).

Finally, there are potentially ethical issues associated with the use of CPAP adherence monitoring systems as a requirement for Medicare payment. CPAP adherence has been shown to be related to socioeconomic class, marital status, race, and psychiatric disease (84–86). These patients may have a difficult time achieving the Medicare adherence patterns and thus certain segments of the population are potentially targets of government-mandated reimbursement discrimination (87, 88).

### Table 3. Continuous Positive Airway Pressure Mask Leak Measurements

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>How Leak Is Measured</th>
<th>Large Leak Threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phillips Respirronics</td>
<td>Intentional leak subtracted from total flow</td>
<td>Leak condition where the leak level exceeds a preset “flow vs. pressure” curve (the averaged leak through all mask exhalation ports at various pressure)</td>
</tr>
<tr>
<td>ResMed</td>
<td>Unintentional leak (device and face interface)</td>
<td>95th percentile leak (&lt;24 L/min with nasal interface and &lt;36 L/min with full face interface)</td>
</tr>
<tr>
<td>Fisher &amp; Paykel</td>
<td>Total leak, including mask and exhaust flow from mask</td>
<td>A leak value of &gt;60 L/min</td>
</tr>
<tr>
<td>DeVilbiss Healthcare</td>
<td>Records high leak flow time as a percentage of the time the leak was above 95 L/min</td>
<td>A leak value of &gt;95 L/min</td>
</tr>
</tbody>
</table>

Definition of abbreviation: CPAP = continuous positive airway pressure.
do not typically include information about total leak minus expected leak or artifact-free leak. It would be helpful for leak to be reported as total leak minus expected leak in a standardized manner across all manufacturers. Mouth leak should be quantified in patients with a nasal mask as compared with leaking around the nasal mask.

Not only should the terminology for CPAP adherence tracking measurements be standardized but there also needs to be the development and acceptance of common report formats among industry partners. Data safety considerations need to be incorporated into these systems. Finally, the medical/legal ramifications of CPAP adherence tracking systems need to be determined.

CONCLUSIONS

OSA is a chronic disease and needs to be managed accordingly (i.e., CPAP adherence should be monitored consistently over time). Increased CPAP usage has been shown to improve OSA outcomes. Third-party payers are requiring documented use of therapy with CPAP tracking systems. CPAP adherence can be reliably determined from CPAP tracking systems. However, the residual events (apnea/hypopnea) and leak data from CPAP tracking systems are not as easy to interpret and the definitions of these parameters differ among the manufacturers of CPAP adherence tracking systems. Nonetheless, ends of the spectrum (very high or low values for residual events or mask leak) appear to be clinically meaningful. The health risks of patients with residual OSA on the event detection algorithms are essentially unknown and need to be studied. CPAP tracking systems intuitively seem useful, although there are few studies showing that CPAP adherence tracking systems improve CPAP adherence or OSA outcomes. Current clinical care systems are not optimally configured for this technology, yet most providers are using CPAP tracking systems to monitor their patients with OSA. Use of CPAP adherence monitoring in real time for clinical decision making based solely on intermediate values for residual AHI or mask leak is unclear, and therefore additional studies are indicated. At present, the data are limited but the technology is young and evolving quickly. Because usage patterns for CPAP are often determined in the first week (74, 90) it seems reasonable that documentation of CPAP adherence should be accepted between 7 and 90 days, rather than the current 31- to 90-day requirement, and CPAP adherence needs to be monitored long term (for as long as the patient is using CPAP). Nomenclature on the CPAP tracking reports needs to be standardized and AHIPflow should be used to describe residual events. It is clear that studies should be performed to examine the usefulness of the CPAP tracking systems and how these systems affect OSA outcomes.

This official statement was prepared by an ad hoc subcommittee of the Sleep and Respiratory Neurobiology Assembly.

Members of the committee:

Richard J. Schwab, M.D. (Chair)
Safwan M. Badr, M.D.
Lawrence J. Epstein, M.D.
Peter C. Gay, M.D.
David Gozal, M.D.
Malcolm Kohler, M.D.
Patrick Levy, M.D.
Atul Malhotra, M.D.
Barbara A. Phillips, M.D., M.P.H.
Irene M. Rosen, M.D., M.S.C.E.
Kingman P. Strohl, M.D.
Patrick J. Strollo, M.D.

Edward M. Weaver, M.D., M.P.H.
Terry E. Weaver, Ph.D., R.N.

Author Disclosures: R.J.S. reported consulting for Apexn ($5,000–24,999) and ApnCare ($5,000–24,999). D.G. reported consulting for Galleanon ($5,000–24,999) and research support from ResMed. A.M. reported consulting for Apex ($10,000–49,999), ApnCare ($1,000–9,999), Galleanon ($1,000–9,999), Philips Respironics ($10,001–49,999), Pfizer ($1,000–9,999), and SGS ($10,000–49,999). K.P.S. reported serving as president of INSLEEP sleep medicine consultants and consulting for Inspire Medical Systems ($10,000–49,999); he served on advisory committees for SleepMed ($5,001–10,000) and Sleep Solutions, Inc. ($5,001–10,000), and received research support from Inspire Medical Systems ($10,000–49,999). P.J.S. reported research support from ResMed ($10,000–49,999). T.E.W. reported licensing agreements for FQSU with Apnex, Cephalon, GlaxoSmithKline, Nova Nordisk, Nova Som, and Philips Respironics; she received royalties or license fees from Apexn ($5,000–24,999), Cephalon ($5,000–24,999), GlaxoSmithKline ($5,000–24,999), Nova Nordisk ($5000–24,999), Nova Som ($5,000–24,999), and Philips Respironics ($5,000–24,999). S.M.B., L.J.E., P.C.G., M.K., P.L., B.A.P., I.M.R., and E.M.W. reported they had no relevant commercial interests.

References


